Calprotectin Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The calprotectin testing market size was valued at USD 0.57 billion in 2025 and is estimated to grow from USD 0.64 billion in 2026 to reach USD 1.23 billion by 2031, at a CAGR of 13.72% during the forecast period (2026-2031). This report is segmented by Assay Type (ELISA, Rapid Immunoassay, CLIA & Other Automated Assays), Application (IBD Diagnosis, Monitoring, IBS Differentiation, Other GI Disorders), Product (Kits & Reagents, Instruments, Consumables & Accessories), End User (Hospitals, Diagnostic Labs, Specialty Centers, Research Institutes), and Geography (North America, Europe, APAC, MEA, South America).

Global Calprotectin Testing Market Trends and Insights

Rising Inflammatory Bowel Disease Prevalence

IBD prevalence is the main long-term demand base for the Calprotectin testing market and guides long-range laboratory capacity planning. A 2024 study estimated 375,140 global incident IBD cases in 2021, which was 88.3% higher than in 1990. The same study identified the strongest growth in people aged 50-54 years, a group with high healthcare use and a greater need for repeated assessment. A 2025 Nature analysis found that India, Brazil, and much of Southeast Asia showed stage-2 incidence patterns, where incidence is still rising before reaching a plateau. This pattern makes emerging-country demand more durable than a short awareness-led increase. Older IBD cohorts also need more relapse surveillance, which increases tests per patient as prevalence matures.

Guideline-Based IBD and IBS Differentiation

Guidelines are making calprotectin a routine decision point rather than an optional laboratory add-on in the Calprotectin testing market. The 2025 BSG guideline placed testing in the primary care pathway for lower gastrointestinal symptoms. The 2025 ACG Crohn’s disease guideline supported a fecal calprotectin cutoff above 50-100 mg/g to distinguish inflammatory from noninflammatory disease. NICE guidance HTG320 remains a procurement reference for NHS laboratory tenders. These documents give laboratories, payers, and clinicians a common basis for incorporating tests into care pathways. The 2026 EOMIFNE consensus also addressed diagnostic, monitoring, and pediatric use in Southern Europe. The Calprotectin testing market benefits when guidance reduces uncertainty around when and how to test.

Assay Standardization and Patient Collection Friction

Cross-assay variation remains a significant clinical constraint for the Calprotectin testing market and prevents simple result comparisons. German proficiency testing data showed Deming regression slopes from 0.37 to 1.91 across 8 calprotectin manufacturers. Results from the same stool sample could therefore differ by nearly a factor of 5 depending on the platform. Thresholds such as 50 µg/g, 100 µg/g, and 250 µg/g were developed on particular methods, so their use on unvalidated platforms may raise false-negative risk. This makes longitudinal comparisons difficult when patients move between ELISA, CLIA, and turbidimetric systems. Stool collection also adds a practical barrier, especially in primary care, where patient compliance is weaker than in specialist settings.

Other drivers and restraints analyzed in the detailed report include:

• Demand for Non-Invasive Disease Monitoring
• Automated and Digitally Connected Testing
• Reimbursement and Endoscopy-Centered Care Pathways

Segment Analysis

ELISA held 43.3% of assay-type revenue in 2025, while CLIA and other automated assays are expected to grow at a 13.9% CAGR through 2031 in the Calprotectin testing market. ELISA retained its position because it has extensive clinical validation and remains the reference comparator in many published studies. Its established sensitivity and specificity evidence supports use in diagnosis and monitoring. Automated formats are gaining ground in high-volume reference laboratories that seek analyzer-integrated workflows. DiaSorin’s LIAISON Calprotectin assay uses the LIAISON XL Analyzer and Q.S.E.T. Device Plus for automated stool extraction . This process reduces manual dilution and can deliver results within a laboratory shift.

Rapid immunoassays serve settings that lack CLIA-category laboratory infrastructure. Their semi-quantitative lateral-flow design provides actionable results in gastroenterology offices, outpatient clinics, and remote settings. ELISA is likely to remain important in batch-oriented laboratories. Automated assays are more suited to integrated health systems pursuing broader laboratory automation. The Calprotectin testing industry therefore has distinct roles for reference methods, automated platforms, and decentralized testing. This division allows rapid formats to expand access without fully replacing laboratory-based testing.

IBD diagnosis represented 38.4% of application revenue in 2025, while IBD monitoring is forecast to grow at a 14.1% CAGR through 2031 in the Calprotectin testing market. Diagnosis remains the clinical entry point because fecal calprotectin can rule out inflammatory disease at the 50 µg/g threshold. A 2024 primary care review described its role in reducing unnecessary gastroenterology referrals when results support an IBS pathway. Monitoring grows faster because biologic treatment requires assessment at baseline, after induction, and during maintenance. The 2025 ACG guideline supported the use of calprotectin cutoffs to distinguish active from quiescent disease. Each review point increases the number of tests per treated patient.

IBS differentiation remains a related use, particularly when a result below 50 µg/g guides care without endoscopy. A 2026 pediatric study at Fudan University found a positive correlation between fecal calprotectin and endoscopic disease activity in 118 pediatric IBD patients. The reported Spearman correlation was 0.572 with p < 0.05. The evidence extends monitoring support to pediatric populations and non-Western clinical settings. Other gastrointestinal disorders, including colorectal cancer screening and postoperative bowel surveillance, remain early-stage applications. The Calprotectin testing market can grow in these areas as the clinical evidence base matures.

Complete Report Scope:

• By Assay Type
  • ELISA
  • Rapid Immunoassay
  • CLIA & Other Automated Assays
• By Application
  • IBD Diagnosis
  • IBD Monitoring
  • IBS Differentiation
  • Other GI Disorders
• By Product
  • Kits & Reagents
  • Instruments
  • Consumables & Accessories
• By End User
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Specialty Centers
  • Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.3% of revenue in 2025, supported by high IBD prevalence, established billing infrastructure, and broad analyzer deployment. The United States led regional demand through repeat testing for diagnosis and monitoring. CPT code 83993 and guidance from the ACG and AGA support use at several points in IBD care. Canada’s IBD prevalence was 0.83% in 2025 and is projected to exceed 1.05% by 2043. This patient base supports steady specialty-center demand. Mexico is an emerging opportunity as private diagnostic chains add access in major urban centers before broad public inclusion.

Europe is the second-largest regional market in the Calprotectin testing market and has a strong external quality assessment culture. The 2025 BSG guideline embedded calprotectin into lower gastrointestinal symptom pathways in the United Kingdom. An NHS service reported a digitally integrated home-testing case study in 2025, using smartphone transmission of lateral-flow results to clinical teams. Germany, France, Italy, and the Netherlands use centralized laboratory networks that favor high-throughput ELISA and turbidimetric formats. Poland’s rising IBD incidence aligns with the stage-2 pattern identified in the 2025 Nature analysis. Spain and Italy also have growing association activity around monitoring protocol standardization.

Asia Pacific is forecast to record a 14.5% CAGR through 2031, the fastest regional growth rate in the Calprotectin testing market. China is extending advanced diagnostic testing to tier-2 and tier-3 hospitals, while local suppliers develop lower-cost point-of-care formats and mid-tier analyzers. India is supported by expanding private laboratory chains and a larger gastroenterologist base serving historically underdiagnosed patients. Japan and South Korea show strong academic adoption. Japanese pediatric evidence linking fecal markers with endoscopic activity can support reimbursement submissions. GCC countries and South Africa are early entry points in the Middle East and Africa, while Brazil and Argentina lead early South American demand through private laboratories and academic gastroenterology networks.

List of Companies Covered in this Report:

• B�HLMANN Laboratories AG
• Eurospital S.p.A.
• Thermo Fisher Scientific
• DiaSorin
• Roche
• Abbott Laboratories
• Bio-Rad Laboratories
• R-Biopharm
• Svar Life Science AB
• Calpro AS
• ALPCO Diagnostics
• Sentinel Diagnostics S.p.A.
• Gentian AS
• Sysmex
• Boditech Med
• BIOHIT Oyj
• Biomerica
• Euroimmun Medizinische Labordiagnostika AG
• Immundiagnostik
• Diesse Diagnostica Senese S.p.A.
• Epitope Diagnostics
• DIAsource ImmunoAssays S.A.
• CerTest Biotec S.L.
• Beckton Dickinson

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support